Search results
Jul 2, 2024 · Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
5 days ago · Introducing Astellas to all our potential investors. Learn about Astellas’ VISION, our business efforts, scale, and our sustainability capabilities. Read More.
Jul 2, 2024 · News from Astellas. Latest and past news available. - Approval marks XTANDI’s third indication for advanced prostate cancer in China -- Approval based on positive results from Phase 3 global ARCHES and China ARCHES studies showing XTANDI plus androgen deprivation therapy (ADT) significantly delays time to PSA progression compared to placebo ...
3 days ago · Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages against tumour cells.
Jul 9, 2024 · Latest Astellas Pharma Inc (4503:TYO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
- 1,585.50
- 1,567.00
- 1,593.00
- 1,590.50
Jun 19, 2024 · ASP-4396 is under clinical development by Astellas Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
People also ask
Who is Astellas pharmaceutical Singapore?
Is Astellas a Japanese company?
Is Astellas Pharma a foreign company?
When did Astellas Pharma Inc (4503 TYO) close?
Jun 20, 2024 · UMass Chan Medical School and pharmaceutical company Astellas Pharma Inc. have entered into a sponsored research agreement to proceed with research for an adeno-associated virus vector mediated gene therapy for the treatment of Alexander disease, a fatal, ultra-rare disease.
